AMENDMENT NO. 1 TO STOCKHOLDERS AGREEMENTStockholders Agreement • March 5th, 2020 • Cellectis S.A. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMarch 5th, 2020 Company Industry JurisdictionThis AMENDMENT NO. 1 TO STOCKHOLDERS AGREEMENT (this “Amendment”), is made and entered into as of May 7, 2018 by and among Calyxt, Inc., a Delaware corporation (the “Company”) and Cellectis S.A., a French société anonyme (“Cellectis”). Terms used, but not otherwise defined, in this Amendment have the meaning assigned to them in the Stockholders Agreement dated July 25, 2017 among the Company, Cellectis and the persons listed on Schedule A thereto (the “Stockholders Agreement”).
SECOND AMENDMENT TO THE MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • March 5th, 2020 • Cellectis S.A. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 5th, 2020 Company IndustryThis SECOND AMENDMENT TO THE MANAGEMENT SERVICES AGREEMENT (the “Second Amendment”) is made and entered into effective as of January 29, 2020 by and among Cellectis S.A. (“CLS”), Cellectis, Inc. (“CLI”), Calyxt, Inc. (“CLX”), and Cellectis Biologics, Inc. (“CBL”), each a Party and together the Parties.
Amendment No. 1 to the License, Development and Commercialization AgreementLicense, Development and Commercialization Agreement • March 5th, 2020 • Cellectis S.A. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 5th, 2020 Company IndustryThis First Amendment (the “Amendment Agreement”) to the License, Development and Commercialization Agreement effective as of March 6, 2019 (the “Initial License Agreement”), shall become effective as of March 4, 2020 (the “Effective Date of the Amendment”) by and between Les Laboratoires Servier, a corporation incorporated under the laws of France having a principal place of business at 50 rue Carnot, 92150 Suresnes, France (“LLS”) and Institut de Recherches Internationales Servier, a corporation incorporated under the laws of France having its principal place of business at 50 rue Carnot, 92150 Suresnes, France (“IRIS”) (LLS and IRIS being together referred to as “Servier”) and Cellectis SA, a company incorporated under the laws of France having a principal place of business at 8, rue de la Croix Jarry, 75013 Paris, France (“Cellectis”). Cellectis and Servier are individually referred to herein as a “Party” and collectively, as the “Parties.”